The BD Max Check-Points CPO assay provides detection of the five most common carbapenemase genes—Klebsiella pneumoniae carbapenemase (KPC), New Delhi metallo-β-lactamase (NDM), oxacillin-hydrolyzing β-lactamase-48 (OXA-48, including OXA-181), Verona integron-encoded metallo-β-lactamase (VIM), and imipenem-hydrolyzing β-lactamase (IMP)—in less than 2.5 hours. Early detection of patients colonized with these organisms can provide the necessary information to implement proper infection control measures.
“We have been using the Check-Points assay on the BD MAX system for routine screening of CPO for nearly two years because it provides us the information we need to isolate or de-isolate our high-risk patients shortly after admission,” John Rossen, assistant professor of medical microbiology at the University Medical Center, Groningen, the Netherlands, and scientific secretary of the ESCMID study group for genomic and molecular diagnostics, said in a release from the companies. “This assay has not only improved our turnaround time, but it also gives us the confidence that we will reduce the risk of transmission and outbreak because patient safety is our number one goal.”
This assay replaces an earlier version of the test from Check-Points and offers an improved workflow and an additional target (IMP).